MeSH term
Frequency | Condition_Probility | Adult | 23 | 0.0 |
Aged | 11 | 0.0 |
Female | 32 | 0.0 |
Humans | 56 | 0.0 |
Male | 30 | 0.0 |
Middle Aged | 12 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Animals | 20 | 0.0 |
Anoxia/*physiopathology | 6 | 14.0 |
Hypercapnia/*physiopathology | 2 | 66.0 |
Motor Neurons/physiology | 2 | 4.0 |
Research Support, U.S. Gov't, P.H.S. | 21 | 0.0 |
Anoxia/physiopathology | 2 | 13.0 |
Positive-Pressure Respiration | 2 | 12.0 |
Pulmonary Ventilation | 2 | 13.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Sleep Stages/*physiology | 2 | 10.0 |
Adolescent | 10 | 0.0 |
Antimalarials/*therapeutic use | 5 | 16.0 |
Child | 10 | 0.0 |
Child, Preschool | 10 | 0.0 |
Chloroquine/*therapeutic use | 4 | 57.0 |
Drug Resistance | 2 | 0.0 |
English Abstract | 2 | 0.0 |
Infant | 10 | 0.0 |
Malaria, Falciparum/*drug therapy | 3 | 25.0 |
Research Support, Non-U.S. Gov't | 26 | 0.0 |
Time Factors | 4 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Comparative Study | 16 | 0.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Blood Pressure/drug effects | 3 | 0.0 |
Vasoconstriction/*drug effects | 2 | 5.0 |
*Respiratory Physiology | 2 | 12.0 |
Electromyography | 2 | 1.0 |
Genotype | 2 | 0.0 |
Biological Markers/analysis | 2 | 0.0 |
*Oxidative Stress | 3 | 1.0 |
Sensitivity and Specificity | 2 | 0.0 |
Drug Combinations | 2 | 0.0 |
Pyrimethamine/therapeutic use | 2 | 15.0 |
Sulfadoxine/therapeutic use | 2 | 25.0 |
Treatment Failure | 4 | 1.0 |
Analysis of Variance | 2 | 0.0 |
Anesthesia, General | 2 | 11.0 |
Models, Biological | 2 | 0.0 |
Rats | 3 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Base Sequence | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Genes, Structural | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Mice | 7 | 0.0 |
Drug Resistance/genetics | 2 | 1.0 |
Gene Amplification | 2 | 0.0 |
Plasmodium falciparum/drug effects/*genetics | 2 | 25.0 |
Logistic Models | 2 | 0.0 |
Respiratory Function Tests | 2 | 1.0 |
Severity of Illness Index | 2 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Risk Factors | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
Lymphocyte Activation | 8 | 0.0 |
Viral Vaccines/*immunology | 2 | 8.0 |
Cell Line | 2 | 0.0 |
Lactoferrin/*genetics | 3 | 25.0 |
Age Factors | 4 | 0.0 |
Retrospective Studies | 2 | 0.0 |
In Vitro | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
Lactoglobulins/*genetics | 2 | 50.0 |
*Breast Feeding | 2 | 3.0 |
Infant, Newborn | 5 | 0.0 |
*Lymphocyte Activation | 5 | 0.0 |
Respirovirus Infections/*immunology | 2 | 66.0 |
Pregnancy | 2 | 0.0 |
Neuronal Plasticity | 2 | 7.0 |
Antigens, Viral/isolation & purification | 2 | 22.0 |
Chickenpox/*immunology | 2 | 33.0 |
Herpesvirus 3, Human/*immunology | 3 | 16.0 |
*Immunity, Cellular | 7 | 5.0 |
Antibodies, Viral/analysis | 2 | 1.0 |
Antigens, Viral | 2 | 9.0 |
Cytomegalovirus/*immunology | 3 | 4.0 |
*Immunosuppression | 2 | 2.0 |
Rosette Formation | 2 | 0.0 |
Kinetics | 2 | 0.0 |
T-Lymphocytes/immunology | 3 | 0.0 |
